Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.
暂无分享,去创建一个
Nikolaus Schultz | Glenn Heller | Hans Lilja | N. Schultz | R. Khanin | H. Scher | H. Lilja | M. Fleisher | D. Danila | G. Heller | Howard I Scher | Daniel C Danila | Martin Fleisher | Aseem Anand | Mingliang Wan | Clifford C Sung | Charles Dai | Raya Khanin | A. Anand | Charles Dai | Mingliang Wan | C. Sung
[1] H. Scher,et al. Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.
[2] C. Parker,et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acet , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Ruud H. Brakenhoff,et al. Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.
[4] Jonathan W. Uhr,et al. Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.
[5] A. Orth,et al. Large-scale analysis of the human and mouse transcriptomes , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[6] W. Gerald,et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Wei Chen,et al. Regulation of the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cells , 2008, Oncogene.
[8] Glenn Heller,et al. Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.
[9] K. Pienta,et al. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.
[10] Kenneth J. Pienta,et al. Circulating Tumor Cells Predict Survival Benefit From Treatment in Metastatic Castration-Resistant Prostate Cancer Editorial Comment , 2009 .
[11] J. Palvimo,et al. FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide™) , 2013, Molecular and Cellular Endocrinology.
[12] Jon W. Huss,et al. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources , 2009, Genome Biology.
[13] H. Scher,et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. , 2011, European urology.
[14] Klaus Pantel,et al. Circulating Tumors Cells as Biomarkers: Progress Toward Biomarker Qualification , 2011, Cancer journal.
[15] J. Carpten,et al. Germline mutations in HOXB13 and prostate-cancer risk. , 2012, The New England journal of medicine.
[16] Andrew J. Vickers,et al. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.
[17] Lisa M McShane,et al. Publication of tumor marker research results: the necessity for complete and transparent reporting. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Howard I. Scher,et al. Circulating Tumor Cells as Biomarkers in Prostate Cancer , 2011, Clinical Cancer Research.
[19] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[20] Jiang Qian,et al. TiGER: A database for tissue-specific gene expression and regulation , 2008, BMC Bioinformatics.
[21] A. D'Amico,et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] H. Klocker,et al. Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. , 2008, Urologic oncology.
[23] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.
[24] Xiaoyu Jia,et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. , 2009, The Lancet. Oncology.
[25] Glen Kristiansen,et al. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. , 2012, The American journal of pathology.
[26] M. Gonen,et al. Concordance probability and discriminatory power in proportional hazards regression , 2005 .
[27] A. Sivachenko,et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.
[28] C. Parker,et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetat , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.